Galectin Therapeutics Inc. (GALT)

[PaPaGriz]

From Lung Disease News yesterday:

"Scientists are studying a drug called GR-MD-02 that could be a treatment for PAH, said Dr. David Fulton, director of the Vascular Biology Center at the Medical College of Georgia (MCG) in a press release. GR-MD-02 acts by blocking gal-3 levels, according to data presented at the 2016 American Thoracic Society Conference. Investigators will continue to develop the drug in collaboration with Atlanta-based Galectin Therapeutics."...

"Fulton and Dr. Scott Barman, pulmonary vascular biologist in the MCG Department of Pharmacology and Toxicology, received a $2.2 million grant from the National Institutes of Health (NIH) to study gal-3 in PAH."